Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients
Study of Association Between Quantity (and Percentage) of Visceral Adipose Tissue and NAFLD-linked Liver Stifness as Mesured by Fibroscan in a Retrospective Cohort of Diabetes Mellitus Patients
Non Alcoholic Fatty Liver Disease (NAFLD) is an emergent disease worldwide, and soon the leading cause of hepatic transplant in the USA. Among this high number of patients, the current challenge is to detect or even predict patients at risk of inflammation (Non Alcoholic or Steatohepatitis or NASH) and end-stage fibrosis, which are the best predictors of liver-related mortality.
Visceral obesity is intimately associated with metabolic disease and adverse health outcomes, such as diabetes, and NAFLD. It has been demonstrated that visceral adipose tissue-linked inflammation was a risk factor of stroke, myocardial infarction, and others metabolic-related complications.
The aim of this study was to evaluate the association of the quantity and percentage of Visceral Adipose Tissue by Dual X-Ray Absorptiometry and liver stiffness by Fibroscan in patients with type 2 diabetes, and other predictors of fibrosis such as FIB-4 and Fibrotest. We retrospectively collected the data of all the diabetic patients who had undergone a DEXA and a Fibroscan between January 1st, 2014 and Decembre 31th, 2019, in the Universitary Hospital of Nancy, France.
調査の概要
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Nancy、フランス、54500
- GUERCI Bruno
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Type 2 diabetes mellitus
- Patients who had undergone a VCTE examen at Universitary Hospital of Nancy between January 1st, 2014 and December 31th, 2019
- - Patients who had undergone a DEXA at Universitary Hospital of Nancy with less than one year of difference with VCTE
Exclusion Criteria:
- Viral, ethylic, drug-linked, genetic, self-immune hepatitis, liver cancer or metatasis ; other causes who could interact with fibroscan or biological markers (thrombocytopenia, undernutrition)
- Type 1 diabetes mellitus
- Weight variation (>5% of body weight) between DEXA mesure and Fibroscan mesure
- Fail of VCTE examination
- High alcohol consumption (>30g/day for men and >20g.day for women)
- Pregnant women
- Other causes of secondary hepatic steatosis (drug-linked, parenteral nutrition, rare diseases...)
- Any other pathology that the investigator would consider not compatible with the research
- Patients in any other research protocol three months before inclusion
- Person referred as in the Public Health code (articles L.1121-5, L.1121-7 and L.1121-8) : pregnant or nursing woman, minor adult, major adult under legal protection, adult unable of giving consent
- Person deprived of their liberty by judicial or administrative decision, person under psychiatric care as described in articles L. 3212-1 and L.3213-1.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Cohort
All the patients with type 2 diabetes followed at Universitary Hospital of Nancy who had undergone a DEXA and a Fibroscan between 2014 and 2019.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Association between quantity of Visceral adipose Tissu and Liver Stiffness
時間枠:July to September 2020
|
Visceral adipose tissu in grams mesured by DEXA, and Liver stiffness in kiloPascal mesured par Vibration-Controlled Transient Elastography
|
July to September 2020
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Association between percentage of Visceral adipose Tissu and Liver Stiffness
時間枠:July to September 2020
|
Visceral adipose tissu in percentage on total fat mass mesured by DEXA, and Liver stiffness in kiloPascal mesured par Vibration-Controlled Transient Elastography
|
July to September 2020
|
Association between quantity of Visceral adipose Tissue and histologic Fibrosis
時間枠:July to September 2020
|
Visceral adipose tissu in grams mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Association between percentage of Visceral adipose Tissue and histologic Fibrosis
時間枠:July to September 2020
|
Visceral adipose tissu percentage on total fat mass mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Determine the diagnostic performances of quantity of Visceral adipose Tissue for histologic fibrosis diagnosis.
時間枠:July to September 2020
|
Visceral adipose tissu in grams mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Determine the diagnostic performances of percentage of Visceral adipose Tissue for histologic fibrosis diagnosis.
時間枠:July to September 2020
|
Visceral adipose tissu percentage on total fat mass mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Determine the diagnostic performances of different biologic markers for histologic fibrosis diagnosis.
時間枠:July to September 2020
|
Histologic fibrosis determined on hepatic biopsy.
|
July to September 2020
|
Build an algorithm with Visceral adipose Tissue mesured and biological markers to predict fibrosis.
時間枠:July to September 2020
|
Prediction algorithm for hepatic fibrosis based on different markers
|
July to September 2020
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
2型糖尿病の臨床試験
-
Centre Hospitalier Universitaire, Amiens募集
-
Jin-Hee AhnAsan Medical CenterわからないHER-2遺伝子増幅 | HER-2 タンパク質の過剰発現
-
AIM Vaccine Co., Ltd.Ningbo Rongan Biological Pharmaceutical Co. Ltd.; LiveRNA Therapeutics Inc.募集
-
AIM Vaccine Co., Ltd.Ningbo Rongan Biological Pharmaceutical Co. Ltd.; LiveRNA Therapeutics Inc.まだ募集していませんSARS-CoV-2
-
AIM Vaccine Co., Ltd.まだ募集していません
-
Ridgeback Biotherapeutics, LPMerck Sharp & Dohme LLC完了
-
Peking UniversityCenters for Disease Control and Prevention, China; Beijing Pinggu District Hospital; Peking University...完了